Eagle Asset Management Inc. boosted its holdings in shares of Edge Therapeutics, Inc. (NASDAQ:EDGE) by 0.2% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 901,359 shares of the biotechnology company’s stock after buying an additional 1,391 shares during the quarter. Eagle Asset Management Inc. owned 2.92% of Edge Therapeutics worth $9,247,000 as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in EDGE. Wells Fargo & Company MN lifted its holdings in Edge Therapeutics by 1.7% during the 1st quarter. Wells Fargo & Company MN now owns 11,942 shares of the biotechnology company’s stock worth $109,000 after buying an additional 200 shares in the last quarter. Russell Investments Group Ltd. increased its position in shares of Edge Therapeutics by 16.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 11,959 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 1,733 shares during the last quarter. Trexquant Investment LP purchased a new stake in shares of Edge Therapeutics in the 1st quarter valued at approximately $143,000. State of Wisconsin Investment Board purchased a new stake in shares of Edge Therapeutics in the 2nd quarter valued at approximately $154,000. Finally, Spark Investment Management LLC purchased a new stake in shares of Edge Therapeutics in the 1st quarter valued at approximately $157,000. Institutional investors own 49.38% of the company’s stock.
In other Edge Therapeutics news, insider Brian A. Leuthner sold 7,500 shares of the firm’s stock in a transaction dated Thursday, August 3rd. The stock was sold at an average price of $10.53, for a total transaction of $78,975.00. Following the transaction, the insider now owns 125,236 shares in the company, valued at $1,318,735.08. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Albert N. Marchio II sold 2,500 shares of the firm’s stock in a transaction dated Tuesday, August 29th. The stock was sold at an average price of $10.42, for a total value of $26,050.00. Following the transaction, the insider now owns 3,361 shares in the company, valued at approximately $35,021.62. The disclosure for this sale can be found here. Over the last quarter, insiders sold 31,000 shares of company stock valued at $319,190. Corporate insiders own 36.19% of the company’s stock.
EDGE has been the topic of a number of recent analyst reports. BidaskClub raised shares of Edge Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 3rd. Zacks Investment Research downgraded shares of Edge Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, August 3rd.
TRADEMARK VIOLATION NOTICE: This news story was published by BBNS and is the property of of BBNS. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://baseballnewssource.com/markets/eagle-asset-management-inc-grows-position-in-edge-therapeutics-inc-edge/1589574.html.
Edge Therapeutics, Inc. (EDGE) opened at 9.54 on Friday. Edge Therapeutics, Inc. has a 52-week low of $7.30 and a 52-week high of $13.50. The stock’s market capitalization is $294.32 million. The company has a 50 day moving average of $10.38 and a 200-day moving average of $9.87.
Edge Therapeutics (NASDAQ:EDGE) last announced its quarterly earnings data on Tuesday, August 1st. The biotechnology company reported ($0.44) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.44). Equities research analysts anticipate that Edge Therapeutics, Inc. will post ($1.87) EPS for the current year.
Edge Therapeutics Profile
Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.
Receive News & Ratings for Edge Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics Inc. and related companies with our FREE daily email newsletter.